Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics develops treatments for serious immunological diseases, with company updates centered on atacicept, a self-administered fusion protein designed to block BAFF and APRIL activity involved in autoantibody production. News commonly covers the atacicept program in IgA nephropathy, related autoimmune kidney disease research, clinical data from the ORIGIN and PIONEER programs, FDA regulatory communications, and preparations tied to potential commercialization.
Other recurring developments include quarterly financial results, balance sheet and financing commentary, participation in health care conferences, board and executive appointments, and equity-based inducement awards under Nasdaq Listing Rule 5635(c)(4).
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Vera Therapeutics, Inc. announced positive interim data from its Phase 2b ORIGIN clinical trial of atacicept in IgA Nephropathy (IgAN), revealing a 41% mean reduction in proteinuria for the 150mg dose group at 24 weeks. The company plans to start a Phase 3 clinical trial in Q2 2023 and expects to release 36-week data from ORIGIN then. Vera reported a net loss of $89.1 million for 2022, increasing from $32.6 million in the previous year. Despite this, it has a strong balance sheet with approximately $188 million from recent follow-on offerings, supporting operations through early 2026.